- |||||||||| STC-1010 / Brenus Pharma
BreAK CRC, a first-in-human phase I/II trial of STC-1010, a new allogenic cancer vaccine for advanced or metastatic unresectable colorectal cancer. (Hall A; Poster Bd #: 295b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2699;
Preclinical efficacy and safety results of STC-1010 murine surrogate underline the capacity of the vaccine combined with immunostimulant in low dose (cyclophosphamide and GM-CSF) associated or not with the standard of care (SoC) chemotherapy (FOLFOX or FOLFIRI) to decrease tumor volume, improve mice survival and enhance tumor T cell infiltration in different syngeneic models of mice... The dose-escalation phase I will evaluate on 9 to 18 patients the tolerability of two STC-1010's dose levels (3x10 6 and 6x10 6 vaccine cells) administered intra-dermally on a weekly basis for 8 weeks, followed by 4 boosts, combined with immunostimulants in low dose (oral cyclophosphamide: 50 mg/day, 3 days before vaccine and GM-CSF: 125or 250
- |||||||||| STC-1010 / Brenus Pharma
Efficacy of the STC-1010 a new allogenic cancer vaccine in different colorectal cancer models (Section 39) - Mar 5, 2024 - Abstract #AACR2024AACR_6526;
In addition, mSTC-1010 associated with immunostimulant (cyclophosphamide and mGM-CSF), combined or not with chemotherapy (FOLFOX or FOLFIRI) led to a significant decrease of tumor volume, a M1-oriented macrophage response (immunohistochemical, iNOS/CD163 >1), and an increase of T lymphocyte infiltration...The good tolerability and reproducible efficiency of the STC-1010 vaccine in these different clinical models allow to plan a first-in-human phase I/II clinical trial for metastatic CRC(mCRC) patients. A dose-escalation and cohort extension phase I followed by a phase IIa with STC-1010 plus immunostimulant, associated to mFOLFOX6 w/o bevacizumab, will be performed for MSS mCRC patients to evaluate the safety and preliminary effectiveness in human.
- |||||||||| STC-1010 / Brenus Pharma
Stimulated tumor cells (STC) vaccine induce response in colorectal cancer (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1434;
A dose-escalation and cohort extension phase I followed by a phase IIa with STC-1010 plus immunostimulant, associated to mFOLFOX6 w/o bevacizumab, will be performed for MSS mCRC patients to evaluate the safety and preliminary effectiveness in human. On the other hand, proteomic characterization approach showed that around 200 proteins involved in resistances, tumor progression and escape are expressed in the vaccine allowing considerable coverage of patients
- |||||||||| STC-1010 / Brenus Pharma
Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4678;
A dose-escalation phase Ia (STC-1010 plus immunostimulant, associated to mFOLFOX6 w/o bevacizumab) will be performed with MSS mCRC patients to evaluate the safety and the recommended phase 2 trial dose (RP2D). A subsequent expansion phase IIa part will assess STC-1010 efficiency, associated with SoC in first-line setting for MSS patients, and in second-line setting after immunotherapy for MSI-H, dMMR or Lynch syndrome mCRC patients.
- |||||||||| STC-1010 / Brenus Pharma
STC-1010 a new therapeutic vaccine promotes tumor cell death (Section 36; Poster Board #17) - Mar 14, 2023 - Abstract #AACR2023AACR_5716;
CD8+ T cells primed with STC-1010-treated DCs promote massive apoptosis of HCT116 and HT29 cells compared to the condition without STC-1010 (p<0,001 for all donors). The benefit of STC-1010 was not detectable with LS174T cells characterized by a low expression of HLA-ABC and used as negative control in this study.CONCLUSION Taken together, our results showed that Brenus STC-1010 human vaccine is an efficient strategy to educate immune system and promote the CRC cells death in vitro lending further support in favor of STC technology based on physical or chemical stimulation and haptenization to generate human cancer therapeutic vaccine.
- |||||||||| STC-1010 / Brenus Pharma
EFFICACY STUDY OF STC-1010 ANTITUMOR VACCINE ASSOCIATED WITH STANDARD CHEMOTHERAPIES ON MC 38 SYNGENEIC COLON CANCER TUMOR MODEL (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1487;
We report efficacy results of three (3 CL-S) cell lines S=stimulated by irradiation and heat shock versus three cell lines (6 CL-S) physically and chemically stimulated (irradiation, heat shock and chemotherapies), both haptenized (H) and administrated with immunostimulant (IS=cyclophosphamide and mGM-CSF) associated w/o to standard chemotherapy FOLFOX or FOLFIRI...Conclusions This third preclinical study confirms efficacy and safety of Brenus STC vaccine stimulated and haptenized alone or with standard chemotherapies associated to immunostimulant. This significant anticancer effect in mice could be explained by mobilization of CD3, CD8, CD4 T cells within the tumors and oriented M1 macrophage immune responses.
|
